• Explore /
  • Poster
  • / BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Abstract Poster

Authors

null

George Follows

Department of Haematology, Addenbrooke’s Hospital NHS Trust, Cambridge, United Kingdom

George Follows , John M. Burke , Sebastian Grosicki , Christine Chen , Alessandro Sanna , Lindsey Elizabeth Roeker , Shuhua Yi , Talha Munir , Fátima de la Cruz , Emmanuelle Ferrant , Zoltán Mátrai , Paolo Ghia , Wojciech Jurczak , Francesc Bosch , Marisa E. Hill , Denise Wang , Ananya Guntur , Ching Ching Leow , Jeff Porter Sharman , Paul M. Barr

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT04666038

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7582)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7582

Abstract #

TPS7582

Poster Bd #

131a

Abstract Disclosures

Similar Posters

First Author: Jennifer Ann Woyach

First Author: Michael Wang

First Author: Martin H. Dreyling

First Author: Toni K. Choueiri